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OBSERVATIONS
Pancreatitis
AssociatedWith
Incretin-Based
Therapies
In recent years, incretin-based therapiessuch as glucagon-like peptide-1 agonists(GLP-1) and dipeptidyl peptidase-IV
inhibitors (DPP-IV) have become impor-
tant therapeutic options for treatment of
type 2 diabetes. Although these agents are
considered safe, long-term safety outcome
studies are lacking. Theoretically, the com-
bination of these two classes of agents could
increase efﬁcacy, but there is no strong
supporting clinical evidence. While both
GLP-1 and DPP-IV agents are approved for
use as monotherapy and with other di-
abetes drugs, the combined use of these
drugs classes has not been approved by the
U.S. Food andDrugAdministration (FDA).
In a recent case report, Patel et al. (1)
noted an improvement in glycemic con-
trol in a patient with type 2 diabetes on a
combination of sitagliptin and exenatide
in addition to glipizide. In a separate ran-
domized noninferiority study, Violante
et al. (2) reported that in patients with type
2diabetes inadequately controlledwithmet-
formin and sitagliptin, the addition of twice-
daily exenatide (ADD group) improved
glycemic control in comparison with the
group switched to exenatide andmetformin
(SWITCHgroup). The primary efﬁcacy out-
come in their study was a change in HbA1c
over a period of 20 weeks. The study
demonstrated a 0.3% reduction in HbA1c
for the ADD group in comparison with the
SWITCH group. Although these studies
highlight the potential beneﬁt of the combi-
nation on glycemic control, the adverse ef-
fects of the combination remain worrisome.
With the inﬂux of reports on GLP-1
and DPP-IV drug-related pancreatitis, there
is a need for close surveillance of these
agents. Acute pancreatitis has been reported
with both exenatide and sitagliptin (3,4).
Our group recently reported a case of fatal
necrotizing pancreatitis in a 76-year-old
woman prescribed drugs fromboth of these
classes (5). The patient had been taking ex-
enatide for years without problems.
However, 2 weeks after her primary care
physician added sitagliptin, she developed
necrotizing pancreatitis. Based on her
history, laboratory studies, and autopsy
report, all other causes of pancreatitis were
ruled out.
Over the last several years postmar-
keting reporting of adverse events to the
FDA has resulted in manufacturer
strengthening of its labeling with regard
to acute pancreatitis. In fact, incretin-
based therapies are now contraindicated
by the FDA for use in patients with a
history of pancreatitis. These data should
be taken into serious account prior to
considering their use in patients with
diabetes mellitus. Given the lack of
randomized studies addressing the long-
term adverse effects of these incretin-
based therapies, we strongly discourage
the use of GLP-1 agonists and DPP-IV
inhibitors in combination. The rapidly
evolving concerns of pancreatitis with
incretin-based agents when used as
monotherapy or in combination impli-
cate the need for additional rigorous
evaluation before widespread use. We
strongly recommend that when prescrib-
ers desire using combination therapies
with the aim of optimizing glycemic
control, they follow guidelines as pre-
viously reported by the American Di-
abetes Association and the European
Association for the Study of Diabetes.
Strict adherence to prescribing guidelines
and a vigilant eye on medication safety
literature should guide management of
individual patients receiving newly
approved medications with potential
life-threatening side effects.
SHRIDHAR N. IYER, MD, PHD, FACP1
ROBERT J. TANENBERG, MD, FACP2
CARLOS E. MENDEZ, MD, FACP3
R. LEE WEST, MD4
ALMOND J. DRAKE, III, MD, FACE2
From the 1Division of Internal Medicine, Albany
Medical Center, Albany, New York; the 2Division of
Endocrinology, Brody School of Medicine, East
Carolina University, Greenville, North Carolina; the
3Diabetes Management Program, Albany VA Medi-
cal Center, Albany, New York; and the 4Department
of Pathology, Brody School of Medicine, East Car-
olina University, Greenville, North Carolina.
Corresponding author: Robert J. Tanenberg, tanenbergr@
ecu.edu.
DOI: 10.2337/dc12-1987
© 2013 by the American Diabetes Association.
Readers may use this article as long as the work is
properly cited, the use is educational and not for
proﬁt, and the work is not altered. See http://
creativecommons.org/licenses/by-nc-nd/3.0/ for
details.
Acknowledgments—No potential conﬂicts
of interest relevant to this article were re-
ported.
S.N.I.wrote themanuscript. C.E.M. reviewed
the manuscript. R.L.W. contributed to the
discussion. A.J.D. edited the manuscript. R.J.T.
is the guarantor of this work and, as such, had
full access to all the data in the study and takes
responsibility for the integrity of the data and the
accuracy of the data analysis.
c c c c c c c c c c c c c c c c c c c c c c c c
References
1. Patel MB, Elmore LK, Edgerton LP, Whalin
LM. Combination exenatide-sitagliptin
therapy used with glipizide in a patient
with type 2 diabetes mellitus. Am J Health
Syst Pharm 2012;69:1044–1048
2. Violante R, Oliveira JHA, Yoon KH, et al.
A randomized non-inferiority study com-
paring the addition of exenatide twice daily
to sitagliptin or switching from sitagliptin
to exenatide twice daily in patients with
type 2 diabetes experiencing inadequate
glycaemic control on metformin and sita-
gliptin. Diabet Med 2012;29:e417–e424
3. U.S. Food and Drug Administration. Drugs:
Information for healthcare professionals: ex-
enatide (marketed as Byetta) [Internet], 2008.
Available from http://www.fda.gov/Drugs/
DrugSafety/PostmarketDrugSafetyInforma-
tionforPatientsandProviders/ucm124713.
htm. Accessed 16 September 2012
4. U.S. Food andDrug Administration. Safety:
Sitagliptin (marketed as Januvia and Janu-
met) –acute pancreatitis [Internet], 2009.
Available from http://www.fda.gov/
Safety/MedWatch/SafetyInformation/Safety
AlertsforHumanMedicalProducts/ucm183800.
htm. Accessed 16 September 16 2012
5. Iyer SN, Drake AJ, West RL, et al. Case report
of acute necrotizing pancreatitis associated
with combination treatment of sitagliptin
and exenatide. Endocr Pract 2012;18:e10–e13
care.diabetesjournals.org DIABETES CARE, VOLUME 36, APRIL 2013 e49
O N L I N E L E T T E R S
